Coronary artery disease test from GE-backed CardioDx gets mixed results in trial
This article was originally published in Clinica
Executive Summary
A trial designed to validate the ability of Corus CAD, CardioDx's gene expression test for coronary artery disease (CAD) has backed the product, but only weakly.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.